CMS Drug Coverage Could Be Driven By Commercial Plan Decisions Under Proposal

The US Centers for Medicare & Medicaid Services is seeking public comment on whether a proposed rule to establish a Medicare coverage pathway to enable Medicare beneficiaries to get access to breakthrough devices at the time of US Food and Drug Administration approval should also apply to drugs and biologics, which traditionally have not experienced the same coverage delays.

The proposed rule follows an Executive Order on Protecting and Improving Medicare for Our Nation’s Seniors, which President Trump issued in October